Evidence map›Paper›PMID 31588978›Full record

ArticleIntensive care medicine2019

Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura.

Elie Azoulay, Philippe R Bauer, Eric Mariotte, Lene Russell, Paul Knoebl, Ignacio Martin-Loeches, Frédéric Pène, Kathryn Puxty, Pedro Povoa, Andreas Barratt-Due and 11 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Intensive care medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Elie AzoulayCentre National Maladie rare des Microangiopathies Thrombotiques, Médecine Intensive et Réanimation, APHP, Saint-Louis Hospital and Paris University, Paris, France. elie.azoulay@aphp.fr.ORCID http://orcid.org/0000-0002-8162-1508
Philippe R BauerDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
Eric MariotteCentre National Maladie rare des Microangiopathies Thrombotiques, Médecine Intensive et Réanimation, APHP, Saint-Louis Hospital and Paris University, Paris, France.
Lene RussellDepartment of Intensive Care, Copenhagen University Hospital, RigshospitaletCopenhagen Academy for Medical Simulation and Education, University of Copenhagen, and the Capital Region of Denmark, Copenhagen, Denmark.
Paul KnoeblDivision of Hematology and Hemostasis Department of Medicine 1, Medical University of Vienna, Vienna, Austria.
Ignacio Martin-LoechesDepartment of Intensive Care Medicine, Multidisciplinary Intensive Care Research Organization (MICRO), St. James's Hospital, St James Street, Dublin 8, Ireland.
Frédéric PèneCentre National Maladie Rare des Microangiopathies Thrombotiques, Médecine Intensive et Réanimation, Cochin Hospital and Paris University, Paris, France.
Kathryn PuxtyDepartment of Intensive Care, Glasgow Royal Infirmary, Glasgow, UK.
Pedro PovoaPolyvalent Intensive Care Unit, Hospital de São Francisco Xavier, Lisbon, Portugal.
Andreas Barratt-DueDepartment of Emergencies and Critical Care, Oslo University Hospital, Oslo, Norway.
Jose Garnacho-MonteroIntensive Care Clinical Unit, Hospital Universitario Virgen Macarena, Seville, Spain.
Julia WendonKing's College Hospital, London, UK.
Laveena MunshiInterdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada.
Dominique BenoitGhent University Hospital, Ghent, Belgium.
Michael von Bergwelt-BaildonIntensive Care in Hematologic and Oncologic Patients, Munich, Germany.
Marco MaggioriniMedical Intensive Care Unit, University Hospital of Zurich, Zurich, Switzerland.
Paul CoppoCentre National Maladie Rare des Microangiopathies Thrombotiques, Service d'Hématologie, Saint-Antoine Hospital and Paris University, Paris, France.
Spero CatalandDepartment of Medicine, Ohio State University, Columbus, OH, USA.
Agnès VeyradierCentre National Maladies Rares des Microangiopathies Thrombotiques, Service d'Hématologie, Lariboisière Hospital and Paris University, Paris, France.
Andry Van de LouwDivision of Pulmonary and Critical Care, Penn State University College of Medicine, Hershey, PA, USA.
Nine-i Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thrombotic thrombocytopenic purpura (TTP) is fatal in 90% of patients if left untreated and must be diagnosed early to optimize patient outcomes. However, the very low incidence of TTP is an obstacle to the development of evidence-based clinical practice recommendations, and the very wide variability in survival rates across centers may be partly ascribable to differences in management strategies due to insufficient guidance. We therefore developed an expert statement to provide trustworthy guidance about the management of critically ill patients with TTP. As strong evidence was difficult to find in the literature, consensus building among experts could not be reported for most of the items. This expert statement is timely given the recent advances in the treatment of TTP, such as the use of rituximab and of the recently licensed drug caplacizumab, whose benefits will be maximized if the other components of the management strategy follow a standardized pattern. Finally, unanswered questions are identified as topics of future research on TTP.

Indexed as

ADAMTS13 ProteinAdrenal Cortex HormonesDisease ManagementHumansIntensive Care UnitsOrgan Dysfunction ScoresPlasma ExchangePurpura, Thrombotic ThrombocytopenicADAMTS13 ProteinADAMTS13 protein, humanAdrenal Cortex HormonesAcute kidney injuryAuto-immune diseaseCardiac failureHemolysisPlasma exchangeThrombocytopenia

Identifiers

PMID31588978

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.